BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Cognito Therapeutics and Ochsner Health Launch Brain Health Collaboratory to Advance New Care Models for Alzheimer’s Disease

  March 25, 2026

   · 

  6 min read
• Press Releases

  TRIANA Biomedicines’ TRI-611 Granted U.S. FDA Fast Track Designation for Treatment of ALK Positive Non-small Cell Lung Cancer

  March 25, 2026

   · 

  3 min read
• Press Releases

  Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition

  March 25, 2026

   · 

  9 min read
• Press Releases

  bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

  March 25, 2026

   · 

  5 min read
• Press Releases

  Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

  March 25, 2026

   · 

  11 min read
• Press Releases

  OS Therapies Granted EMA’s Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma

  March 25, 2026

   · 

  6 min read
• Press Releases

  Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

  March 25, 2026

   · 

  1 min read
• Press Releases

  Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

  March 25, 2026

   · 

  6 min read
• Press Releases

  Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

  March 25, 2026

   · 

  5 min read
• Press Releases

  BeyondSpring Reports 2025 Year-End Financial Results

  March 25, 2026

   · 

  12 min read